Brodalumab binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. The IL-17 pathway plays a major
Orphan status for Betalutin will provide the company several advantages, such as reduced costs related to the clinical development program, as well as commercial exclusivity for ten years
Under the IND application, the company will be able to move forward in the third quarter of 2014 with its planned US-based Phase II clinical trial designed to
The cloud-based platform will increase efficiencies of projects and trials for pharmaceutical and biotech companies worldwide. Projecis is being used by Synergy to track projects and keep client
Under the deal, Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales. InSite Vision chief executive
The studies are designed to assess the efficacy and safety of ALKS 5461 in patients suffering from MDD who have had an inadequate response to commonly prescribed drugs,
The agreement formalizes the working relationship between ScripsAmerica and RapiMed’s manufacturer. Both the firms have been working together and just completed ScripsAmerica’s first order ticketed for Hong Kong
The acquisition of Idenix is expected to expand Merck’s portfolio of investigational therapies for hepatitis C. Merck Research Laboratories president Roger Perlmutter said Idenix has established a promising
Onychomycosis is a common and destructive nail infection that is currently undertreated due to the limitations of available treatments. At present, over-the-counter (OTC) or prescription topical treatments provide
The trial is designed to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of increasing doses of AG-348 for 14 days. AG-348 is a first-in-class, orally available activator of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.